| Literature DB >> 23984353 |
Jen-Yang Tang1, Li-Yeh Chuang, Edward Hsi, Yu-Da Lin, Cheng-Hong Yang, Hsueh-Wei Chang.
Abstract
This study computationally determines the contribution of clinicopathologic factors correlated with 5-year survival in oral squamous cell carcinoma (OSCC) patients primarily treated by surgical operation (OP) followed by other treatments. From 2004 to 2010, the program enrolled 493 OSCC patients at the Kaohsiung Medical Hospital University. The clinicopathologic records were retrospectively reviewed and compared for survival analysis. The Apriori algorithm was applied to mine the association rules between these factors and improved survival. Univariate analysis of demographic data showed that grade/differentiation, clinical tumor size, pathology tumor size, and OP grouping were associated with survival longer than 36 months. Using the Apriori algorithm, multivariate correlation analysis identified the factors that coexistently provide good survival rates with higher lift values, such as grade/differentiation = 2, clinical stage group = early, primary site = tongue, and group = OP. Without the OP, the lift values are lower. In conclusion, this hospital-based analysis suggests that early OP and other treatments starting from OP are the key to improving the survival of OSCC patients, especially for early stage tongue cancer with moderate differentiation, having a better survival (>36 months) with varied OP approaches.Entities:
Mesh:
Year: 2013 PMID: 23984353 PMCID: PMC3741931 DOI: 10.1155/2013/359634
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Algorithm 1Pseudocode of the Apriori algorithm.
Algorithm 2The first pass of the Apriori algorithm.
Algorithm 3Pseudocode of the function apriori-gen().
Demographic data of 493 enrolled patients with OSCC.
| Characteristics | Survived months |
| 5-year survival (%) |
| ||
|---|---|---|---|---|---|---|
| Total | >36 group | <36 group | ||||
| Age | 0.7786 | 0.5556 | ||||
| <30 | 7 | 3 | 4 | 71.4 | ||
| 30~50 | 228 | 125 | 103 | 77.2 | ||
| 50~70 | 236 | 129 | 107 | 79.2 | ||
| >70 | 22 | 14 | 8 | 63.6 | ||
| Primary Site | 0.7915 | 0.1957 | ||||
| Lip | 36 | 24 | 12 | 86.1 | ||
| Cheek mucosa | 184 | 103 | 81 | 83.2 | ||
| Gum | 42 | 25 | 17 | 71.4 | ||
| Tongue | 175 | 88 | 87 | 72.0 | ||
| Mouth floor | 19 | 11 | 8 | 68.4 | ||
| Palate | 5 | 3 | 2 | 60.0 | ||
| Retromolar | 27 | 15 | 12 | 77.8 | ||
| Vestibule | 2 | 1 | 1 | 100.0 | ||
| Nonspecific | 3 | 1 | 2 | 100.0 | ||
| Laterality∗3 | 0.3965 | 0.8612 | ||||
| 00 | 37 | 22 | 15 | 73.0 | ||
| 01 | 230 | 123 | 107 | 79.1 | ||
| 02 | 223 | 123 | 100 | 76.7 | ||
| 03 | 3 | 3 | 0 | 66.7 | ||
| 04 | 0 | 0 | 0 | NA | ||
| Grade/differentiation | 0.1476 |
| ||||
| 01 | 287 | 156 | 131 | 80.1 | ||
| 02 | 123 | 60 | 63 | 65.0 | ||
| 03 | 7 | 5 | 2 | 57.1 | ||
| 04 | 1 | 1 | 0 | 100.0 | ||
| 09 | 75 | 49 | 26 | 89.3 | ||
| Regional lymph nodes examined | 0.1550 | 0.1424 | ||||
| <5 | 285 | 160 | 125 | 80.4 | ||
| >10 | 134 | 65 | 69 | 73.1 | ||
| 5~10 | 73 | 45 | 28 | 74.0 | ||
| Clinical stage group | 0.0749 | 0.5689 | ||||
| Stage 0 | 4 | 0 | 4 | 75.0 | ||
| Stage 1 | 141 | 79 | 62 | 80.1 | ||
| Stage 2 | 73 | 47 | 26 | 71.2 | ||
| Stage 3 | 131 | 69 | 62 | 77.1 | ||
| Stage 4 | 82 | 50 | 32 | 72.0 | ||
| Pathologic stage group | 0.2540 | 0.0514 | ||||
| Stage 0 | 2 | 2 | 0 | 100.0 | ||
| Stage 1 | 215 | 112 | 103 | 82.3 | ||
| Stage 2 | 92 | 52 | 40 | 75.0 | ||
| Stage 3 | 31 | 15 | 16 | 74.2 | ||
| Stage 4 | 58 | 24 | 34 | 67.2 | ||
| Clinical tumor size | 0.3967 |
| ||||
| <2 cm | 162 | 100 | 62 | 87.0 | ||
| 2~4 cm | 244 | 134 | 110 | 71.3 | ||
| >4 cm | 33 | 19 | 14 | 66.7 | ||
| Pathology tumor size | 0.4417 |
| ||||
| <2 cm | 197 | 114 | 83 | 81.7 | ||
| 2~4 cm | 183 | 94 | 89 | 69.4 | ||
| >4 cm | 25 | 14 | 11 | 72.0 | ||
| OP group∗4 |
|
| ||||
| 01 | 385 | 238 | 147 | 81.6 | ||
| 02 | 27 | 14 | 13 | 66.7 | ||
| 03 | 81 | 19 | 62 | 61.7 | ||
∗1 P value for the comparison of the survival between >36 and <36 months groups.
∗2 P value for 5-year survival among the items of the same characteristics group.
∗30: unknown primary site or the shape of the organ is not paired; 1: the primary site is originated from the right side; 2: the primary site is originated from the left side; 3: only one side is invaded but it is not clear which side (R't or L't) it is originated from; 4: both sides are invaded but the origin of the primary site is not clear and the chart record describes only one primary site.
∗4OP group for 01: OP only; 02: OP→IA; 03: OP→CT, OP→CT + IV, OP→CT→RT, OP→IA→RT, OP→IV,OP→IV→RT, OP→RT, OP→RT + CT,OP→RT + IV, OP→RT→CT, OP→RT→IA, OP→RT→IV. Symbols: OP: operation; IA: intraarterial chemotherapy; CT: oral chemotherapy; IV: intravenous chemotherapy; RT: radiotherapy; →: then.
Ranking of the top 10 best rules found in survival larger than 36 months.
| Body∗1 | No. | Head∗1 | No. | Confidence | Lift∗2 | Leverage | Conviction |
|---|---|---|---|---|---|---|---|
| Grade/differentiation = 2 | 49 | Primary site = tongue | 27 | 0.55 | 1.91 | 0.05 | 1.52 |
| Primary site = tongue | 78 | Grade/differentiation = 2 | 27 | 0.35 | 1.91 | 0.05 | 1.23 |
| Primary site = tongue | 70 | Grade/differentiation = 2 | 27 | 0.39 | 1.9 | 0.05 | 1.27 |
| Grade/differentiation = 2 | 55 | Primary site = tongue | 27 | 0.49 | 1.9 | 0.05 | 1.41 |
| Grade/differentiation = 2 | 60 | Primary site = tongue | 27 | 0.45 | 1.88 | 0.05 | 1.34 |
| Primary site = tongue | 65 | Grade/differentiation = 2 | 27 | 0.42 | 1.88 | 0.05 | 1.3 |
| Primary site = tongue | 88 | Grade/differentiation = 2 | 27 | 0.31 | 1.81 | 0.04 | 1.18 |
| Grade/differentiation = 2 | 46 | Primary Site = tongue | 27 | 0.59 | 1.81 | 0.04 | 1.55 |
| Grade/differentiation = 2 | 60 | Primary site = tongue | 27 | 0.45 | 1.74 | 0.04 | 1.31 |
| Primary site = tongue | 70 | Grade/differentiation = 2 | 27 | 0.39 | 1.74 | 0.04 | 1.24 |
∗1Stages 0 to 3 of clinical stage group and pathologic stage group as shown in Table 1 are regarded as early and stage 4 is regarded as late stage in Table 2.
∗2The best rules with lift >1.5 were shown here.